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ANALISIS LC-MS/MS HOMOSISTEIN PLASMA DAN PENYELIDIKAN 
TENTANG KAITAN PARAS HOMOSISTEIN DENGAN NEUROPATI 
PERIFERAL DALAM KALANGAN PESAKIT DIABETES 
 
ABSTRAK  
Suatu kaedah LC/MS-MS untuk mengukur paras homosistein plasma dari 
sampel manusia telah dihasilkan. Kaedah ini melibatkan penyediaan sampel yang 
mudah dan telah menunjukkan kepersisan, kespesifikan, kesensitifan dan kejituan 
yang baik. Dengan itu, kaedah ini boleh digunakan untuk memeriksa aras 
homosistein sampel klinikal dalam bilangan yang besar. Di samping itu, kaedah ini 
juga dibandingkan dengan kaedah imunoasai yang digunakan oleh makmal patologi 
komersial untuk pengukuran paras homosistein. Kedua-dua kaedah ini menunjukkan 
kejituan yang baik dan min perbezaan yang rendah antara satu sama lain. Dua puluh 
enam peratus daripada 260 pesakit kencing manis dengan neuropati peripheral yang 
direkrut mempunyai paras homosistein yang tinggi. Terdapat lebih ramai lelaki 
daripada perempuan di dalam kumpulan hiperhomosistein (homosistein ≥15µM). 
Paras homosistein adalah berkaitan secara langsung dengan paras kreatinina pesakit 
kajian ini, manakala paras vitamin B12 dan asid folik adalah berhubungan songsang 
dengan paras homosistein pesakit. Kajian ini telah mendapati bahawa paras 
homosistein tidak berkorelasi dengan keterukan neuropati kencing manis. Walau 
bagaimanapun, umur, jantina dan jangka masa pesakit menghidapi kencing manis 
adalah berhubungan langsung dengan ketenatan neuropati. Golongan pesakit yang 
berumur lebih tinggi dan jantina lelaki mempunyai min skor gangguan neuropati 
yang tinggi. Pesakit yang dijangkiti penyakit kencing manis untuk tempoh yang lebih 
panjang juga mempunyai min skor gangguan neuropati yang lebih tinggi.  
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LC-MS/MS ANALYSIS OF PLASMA HOMOCYSTEINE AND 
INVESTIGATION ON THE ASSOCIATION OF HOMOCYSTEINE LEVELS 
WITH DIABETIC PERIPHERAL NEUROPATHY 
 
ABSTRACT 
 A simple LC-MS/MS method was developed to measure homocysteine level 
in human plasma collected from diabetic patients. This method which involves 
simple sample preparation showed good precision, specificity, sensitivity and 
accuracy. Thus, it can be used to screen a vast number of clinical samples. This 
method‘s results were compared with commercial laboratory results derived from the 
immunoassay method. Both methods showed good accuracy with low mean 
difference. Of the 260 patients recruited with peripheral neuropathy, 26% showed 
hyperhomocysteinemia (homocysteine ≥15µM). The male gender was more 
prominent in the hyperhomocysteine group. Homocysteine level was directly 
associated with creatinine, while homocysteine level was inversely correlated with 
the vitamin status (B12 and folic acid). No correlation was observed between 
homocysteine level and severity of neuropathy in the present study. However, age, 
gender and duration of diabetes were associated with neuropathy severity. Higher age 
group patient and the male gender recorded higher means in neuropathy impairment 
score. A higher mean neuropathy impairment score was also observed with longer 
duration of diabetes.   
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CHAPTER 1  
LITERATURE REVIEW 
  
1.1 Diabetes Mellitus 
Diabetes mellitus is a chronic metabolic disease characterised by high blood 
glucose levels resulting from defects in insulin secretion, insulin action, or both. 
Diabetes mellitus is diagnosed as having fasting plasma glucose level of more than 
7.0mmol/l, HbA1c≥6.5% or two-hour plasma glucose of more than 11.1mmol/l 
during an oral glucose tolerance test (OGTT) (American Diabetes Association, 2014). 
  
Diabetes can be classified into four clinical categories. Type 1 diabetes 
mellitus is characterised by the body‘s inability to produce insulin due to an 
autoimmune destruction of the pancreatic beta cells, whereas Type 2 diabetes is a 
non-insulin dependent illness, and it occurs due to beta cells secretory defects on the 
background of insulin resistance. There are other specific types of diabetes due to 
other causes, such as genetic defects in beta cells function, genetic defects in insulin 
action, and diseases of the exocrine pancreas. Gestational diabetes mellitus (GDM) is 
also one of the categories of diabetes (American Diabetes Association, 2014). 
 
The prevalence of diabetes is rising worldwide, threatening to reach pandemic 
levels by 2030. In Malaysia, the fourth National Health and Morbidity Survey 
reported that the prevalence of type 2 diabetes mellitus for adults aged 18 years and 
above was 15.2% (Feisul et al., 2014; Mustapha et al., 2014). This figure is projected 
to rise to 21.6% by year 2020 (Feisul and Azmi, 2013).  
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Diabetes mellitus is a major public health concern as it causes other medical 
comorbidities, disabilities and premature mortality. Direct and indirect effects of 
hyperglycemia on human vascular tissue are the major causes of morbidity and 
mortality in Type 1 and 2 diabetic patients. Complications of diabetes mellitus 
include nephropathy, retinopathy, coronary arterial diseases, peripheral arterial 
diseases, stroke and neurodegenerative disorder like Alzheimer Disease. (Laakso, 
2011; Forbes and Copper, 2013).  
 
Diabetes Mellitus is a metabolic disorder. Metabolic damage as a result of 
hyperglycemia has a direct effect on nerves causing nerve damage leading to painful 
neuropathy. The condition is also exacerbated by decreased blood flow to the nerves 
due to microvascular complications of diabetes. The anatomy of the peripheral 
nervous system which is covered by perineurium, endoneurium is penetrated by only 
a few transperineurial arterioles. Thus, the vascular supply to the peripheral nervous 
system is sparse and there will be a lack of autoregulation and blood flow in the 
peripheral nerve (Smith, 1977; Yagihashi et al.¸ 2011). A noticeable structural 
change in diabetic nerves due to thickened and multilayered basement membranes, 
cell debris of pericytes and endothelial cell disruption are shown in endoneurial 
microvessels. In addition, impaired blood supply in diabetic nerves is seen in 
epineurial microvessels innervation (Grover-Johnson et al., 1981; Tesfaye et al., 
1994; Yagihashi et al., 2011). Poor management of the condition can lead to 
gangrenous injuries and limb amputation. Thus, diabetic neuropathy is the most 
common and debilitating complication of diabetes. 
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1.2 Complications of Diabetes Mellitus 
1.2.1 Types of Complications 
Atherosclerosis results in chronic inflammation to the arterial wall of the 
coronary and peripheral vascular system. The metabolic abnormalities of diabetes 
such as hyperglycemia, increased free fatty acids, and insulin resistance contribute to 
vascular dysfunction. These occur by decreasing the bioavailability of nitric oxide 
(NO), increasing the oxidative stress, disturbances of intracellular signal transduction, 
and activation of receptors for advanced glycation end products (AGE). All these 
abnormalities will lead to atherosclerosis and increase the risk of adverse 
cardiovascular events in patients with diabetes and atherosclerosis (Creager and 
Lüscher, 2003). 
 
Cardiovascular disease (CVD) is the leading cause of death in patients with 
Type 2 diabetes. People with diabetes, particularly Type 2 diabetes will have greater 
risk factors for CVD, which include age, dyslipidemia, hyperglycemia, hypertension, 
obesity, and tobacco use. These factors will cause an injury to the vascular 
endothelium and lead to macrovasculopathy and CVD in Type 2 diabetic patient 
(Beckman et al., 2002). According to Haffner et al. (1998), there is a 5 fold higher 
risk of people with diabetes developing a myocardial infarction (MI) and a 2 fold 
increase risk of recurrent MI compared to people who had an MI previously but do 
not have diabetes history. After an occurrence of MI in people with diabetes, they 
have a growing risk for congestive heart failure and death (Malmberg et al., 2000).  
 
Furthermore, people with diabetes have an increased incidence of 
independent risk factor for stroke. The presence of diabetes increases the risk of 
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intracranial and extracranial atherosclerosis and thus affects the cerebrovascular 
circulation. People with both complications of diabetes and stroke have more 
neurological deficits and disability, and also a higher incidence of stroke recurrence. 
Hyperglycemia occurs to be a significant predictor of fatal and non-fatal stroke, and 
death from stroke (Sasaki et al., 1995). In addition, there is an association between 
elevated blood levels of chronic inflammatory markers and higher risk of stroke in 
people with diabetes (Engstrom et al., 2003).  
 
Peripheral Arterial Disease (PAD) is characterised by occlusion of lower 
extremity arteries, causing intermittent claudication and pain that appears 
reproducibly with walking, resulting in functional impairment and disability (Vogt et 
al., 1994; Schainfeld, 2001; McDermott et al., 2004). The determination of PAD in 
diabetes has been difficult as most incidents occur asymptomatically, no uniform 
screening modalities are available and its pain perception is blunted due to peripheral 
neuropathy. Diabetes and smoking are the strongest risk factors for PAD. Others 
include elevated C-reactive protein level, apolipoprotein B, lipoprotein a, fibrinogen, 
glycation hemoglobin, homocysteine, and plasma viscosity, duration and severity of 
diabetes, hypertension, dyslipidemia and history of CVD (American Diabetes 
Association, 2003; Al-Delaimy et al., 2004; Wattanakit et al., 2005). There is a 
strong association between diabetes with femoral-popliteal and tibial PAD. People 
with diabetes and PAD are at a higher risk of presenting an ischemic ulcer, gangrene 
and lower-extremities amputation. PAD is also a marker for systemic vascular 
disease; contributing to an increased risk of myocardial infarction (MI), stroke and 
death (American Diabetes Association, 2003).  
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Diabetic nephropathy, one of the complications of diabetes, is preceded by 
microalbuminuria which is defined by albumin excretion of 30-299 mg/24 hours. 
This will typically progress to overt albuminuria and then to diabetic nephropathy. 
Comparing with the European populations, the risks of impaired fasting glucose and 
of impaired glucose tolerance in citizens of South-East Asian origin are higher (Gray 
et al., 2010). Furthermore, the prevalence of any type of chronic kidney disease and 
its rate of progression, including diabetic nephropathy, is significantly higher in 
citizens of Asian origin, as observed both in the UK (Lightstone et al., 1995) and in 
Canada (Barbour et al., 2010). This result is presumably due to the different genetics 
and lifestyle. The characteristics of diabetic nephropathy include thickening of 
glomerular basement membrane and glomerular hyperfiltration, which will lead to 
mesangial extracellular matrix expansion which increases urinary albumin excretion 
and progresses to glomerular and tubular sclerosis and renal failure (Van Dijk and 
Berl, 2004; Bloomgarden, 2005; Fowler, 2008). The risk factors for diabetic 
nephropathy are hyperglycemia, longer duration of diabetes, age, dyslipidemia, 
hypertension and obesity (Ismail et al., 1999; Timothy and Peter, 2000; Kramer et al., 
2005). 
 
Diabetic retinopathy affects the peripheral retina, macula, or both and it is the 
leading cause of visual disability and blindness. The prevalence of diabetic 
retinopathy increases with prolonged duration of diabetes (Donald et al., 2003). Few 
pathological mechanisms that will lead to diabetic retinopathy include existence of 
aldose reductase, osmotic stress, glycoprotein injuries effect, hyperglycemia induced 
cellular injury and production of growth factors (Fowler, 2008). The onset of 
histological marker of diabetic retinopathy is the loss of pericytes, which will then 
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interfere with capillary constriction, new capillary generation and vessels protection 
against continuous exposure to noxious molecules (Cade, 2008).  
 
1.2.2 Common Mechanism of Complications in Diabetes Mellitus 
The pathophysiology of vascular disease in diabetes involves abnormalities in 
endothelial, vascular smooth muscle cells, and platelet formation. The common 
mediator in endothelial cells dysfunction is derangement of nitric oxide (NO) 
bioavailability. The presence of NO is vital as it stimulates vasodilatation and 
mediates inflammation (Wallace, 2005). NO also inhibits vascular smooth muscle 
cell migration and proliferation, and limits platelet activation. However, there are 
some mechanisms that lead to the loss of function of NO, including hyperglycemia, 
insulin resistance, and free-fatty acid production. Hyperglycemia blocks the function 
of endothelial nitric oxide synthase (NOS) and enables the production of reactive 
oxygen species, which will impair the endothelial vasodilation (Funk et al., 2012). 
Hyperglycemia also increases the production of advanced glycation end-product 
(AGE), which inhibits NO production, impairs vasodilatory response in diabetes and 
causes an overproduction of vasoconstrictors, such as endothelin-1 (Rask-Madsen 
and King, 2007; Linden et al., 2008). Endothelin-1 induced oxidative stress, 
promotes inflammation and caused endothelial dysfunction (Touyz et al., 2004). 
 
Insulin stimulates endothelial cells NO vasodilatation and hence, improves 
the NOS activity. In the case of Type 2 diabetes mellitus, insulin signal transduction 
via the phosphatidylinositol-3 kinase (PI-3Ks) pathway is impaired, and insulin is 
less able to activate NOS and produce NO (Dresner et al., 1999; Inoguchi et al., 
2000). Insulin resistance is associated with elevations of free fatty acids (FFA). The 
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existence of FFA activates protein kinase C (PKC), inhibits (PI-3Ks), and produces 
reactive oxygen species. This will decrease NOS activity. In response to endothelial 
injury, oxidized lipids will be accumulated. Angiotensin II will promote the oxidation, 
and then the monocytes will infiltrate the arterial wall and differentiate into 
macrophages, which accumulate oxidized lipid to form foam cells. Foam cells 
stimulate macrophage proliferation and attract T-lymphocytes. T-lymphocytes will 
then induce smooth muscle cell proliferation and collagen accumulation in the 
arterial wall. The rupture of the lipid-rich atherosclerotic lesions leads to acute 
vascular infarction (Boyle et al., 2007).  
 
Diabetes causes functional abnormalities in Vascular Smooth Muscle cells 
(VSMC), including reductions in (PI-3Ks), increase in oxidative stress and up 
regulations of PKC, receptors for AGE, and nuclear factor-kB (NF-kB). These 
changes promote atherosclerosis lesions and may increase VSMC apoptosis and 
tissue factor production (American Diabetes Association, 2003). Patients with 
diabetes have increased platelet aggregation due to oxidative stress, caused by 
platelet uptake of glucose in endothelial cells. Platelets in diabetic patients have 
increased glycoprotein Ib and IIb/IIIa receptors expression, which is involved in 
thrombosis. Abnormalities in platelet promote atherosclerosis, plaque disruption and 
atherothrombosis (American Diabetes Association, 2003). 
 
1.3 Neuropathic Pain 
1.3.1 Introduction 
Neuropathic pain is caused by abnormal physiology of peripheral or central 
nervous system. Unlike physiologic pain, neuropathic pain does not arise from the 
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activation of primary afferent neurons (nociceptors) and is not related to the 
inflammatory response in the peripheral nervous system after tissue damage or 
inflammation (Dworkin et al., 2003). Neuropathic pain and physiologic pain are 
different in many ways. Physiologic pain serves to warn and protect the individual 
against injury and usually subsides with time, while neuropathic pain serves no 
useful purpose and it is usually sustained and chronic. Neuropathic pain mechanism 
is complex, multifactorial, and evolves over time (Beydoun and Backonja, 2003; 
Dworkin et al., 2003).  
 
1.3.2 Pathophysiology of Neuropathic Pain 
Neuropathic pain results from cellular changes that occur in both the 
peripheral and central nervous systems, leading to sensitisation to pain signal 
transmission. Figure 1.1 showed pathophysiological mechanisms of neuropathic pain. 
In the primary afferent pathways connection with the spinal cord dorsal horn, 
nociceptive C-fibres terminate at spinothalamic projection neurons in upper laminae, 
whilst non-nociceptive myelinated A-fibres project to deeper laminae. Ongoing 
discharges of peripheral afferent fibres that release excitatory aminoacids and 
neuropeptides within dorsal horn of the spinal cord lead to postsynaptic changes of 
second-order nociceptive neurons. These changes include the expression of voltage-
gated sodium channels or the phosphorylation of N-methyl-D-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptors (Hains et 
al., 2004; Ultenius et al., 2006). Neuronal hyperexcitability that enables low-
threshold mechanosensitive Aβ and Aδ afferent fibres is induced to activate second-
order nociceptive neurons. The second-order projection neuron is a wide dynamic 
range (WDR) type. It receives a direct synaptic input from the nociceptive terminals  
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Figure 1.1 Pathophysiological mechanisms of neuropathic pain (Baron et al., 2010).  
A. Primary afferent pathways and their connections in the spinal cord dorsal horn.  
C-fibres (red); spinothalamic projection neurons (yellow); A-fibres (blue); microglia 
(grey); GABAergic interneurons (green). 
B. Peripheral changes at primary afferent neurons after a partial nerve lesion, leading 
to peripheral sensitisation. Damaged and degenerated axon (axon 1 and 3); Axon are 
connected with peripheral end organ (axon 2 and 4). 
C. Spontaneous activity in C-nociceptors induces secondary changes in central 
sensory processing. Second-order nociceptive neuron (star in yellow neuron); 
inhibitory interneurons (green). 
D. Peripheral nerve injury. Spinal cord glial cell (grey). 
(AMPA= α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid, GABA=gamma-
aminobutyric acid, KA=kainite, NMDA=N-methyl-D-aspartate, TRPV1=transient 
receptor potential V1, NE=norepinephrine, 5HT=5-hydroxytryptamine) 
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and also multisynaptic input from myelinated A-fibres. Futhermore, interaction with 
microglia facilitates synaptic transmission. GABAergic interneurons normally exert 
inhibitory synaptic input on the WDR neuron. After a peripheral nerve lesion, loss of 
inhibitory GABAergic interneurons in the spinal cord occurs (Moore et al., 2002). 
Mechanical and thermal hyperalgesia will be attenuated in the prevention of 
interneurons cell death, indicate disinhibition will lead to neuropathic pain (Scholz et 
al., 2005).  
 
Central mechanism of neuropathic pain is initiated by tachykinin and 
neurotransmitter released from peripheral nociceptors (Beydoun and Backonja, 2003). 
Meanwhile, spontaneous activity in C-nociceptors induces secondary changes in 
central sensory processing, leading to spinal cord hyperexcitability. This changes 
causes input from mechanoreceptive A-fibres to be perceived as pain. Several 
presynaptic molecular structures (opioid receptors and calcium channels) and 
postsynaptic molecular structures (glutamate receptors, α-amino-3-hydroxy-5-
methyl-4-isoxasole propionic acid /kainite receptors, sodium/5-hydroxytryptamine 
receptors, gamma-aminobutyric acid receptors and sodium channels) are involved in 
central sensitization (Baron et al., 2010). Besides, increased intracellular calcium due 
to prolonged binding of tachykinin and neurotransmitter to neural receptors had 
activated the N-methyl-D-aspartate (NMDA) receptors. This changes lead to a lower 
activation threshold, increased response to stimuli and enlarged receptive field of 
spinal dorsal horn neurons (Siddal and Cousins, 1997; Beydoun and Backonja, 2003). 
Moreover, between neurons ephaptic conduction, neuronal reorganisation and central 
inhibition may occur in central neuropathic pain (Attal, 2000; Bridges et al., 2001). 
Inhibitory interneurons and descending modulatory control systems are dysfunctional 
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after nerve lesions, leading to disinhibition of spinal cord dorsal horn neurons and 
lead to central sensitization (Baron et al., 2010). The clinical correlates include 
allodynia, secondary hyperalgesia, and sympathetically maintained pain. A list of 
central neuropathic pain syndromes includes compressive myelopathy from spinal 
stenosis, HIV myelopathy, multiple sclerosis pain, Parkinson‘s disease pain, 
poststroke pain, spinal cord injury pain and syringomyelia (Dworkin, 2002; Dworkin 
et al., 2003).  
   
Peripheral neuropathic pain mechanism is initiated by release of chemicals 
from damaged cells and inflammatory cells (Siddall and Cousins, 1997). This 
chemicals act to sensitize nociceptors. As a result, sodium and calcium channels are 
altered and the threshold for depolarisation is lowered, leading to peripheral 
sensitization (Beydoun and Backonja, 2003). Meanwhile, peripheral changes at 
primary afferent neurons (nociceptive C-fibers, non-nociceptive myelinated A-fibers) 
after partial nerve lesion will lead to peripheral sensitization. The lesion triggers the 
expression of sodium channels on damaged C-fibers, increases expression of sodium 
channels in dorsal root ganglia and around the terminal injury site of injured axons, 
and increases expression of α2δ calcium channels (Baron, 2006; Cohen and Mao, 
2014). Furthermore, there will be collateral sprouting of primary afferent neurons, 
recruitment of nearby uninjured nociceptors and coupling between the sympathetic 
nervous system and sensory nervous system occur in peripheral neuropathic pain 
(Bridges et al., 2001). Nerve growth factor that are associated with Wallerian 
degeneration are released in the vicinity of spared fibers, triggering channel and 
receptor expression (sodium channels, TRPV1 receptors, adrenoceptors) on 
uninjured fibers (Baron, 2006). Wallerian degeneration decreases the size of the cell 
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body and the axon diameter, and cause neuronal death. These changes decrease 
intraepidermal nociceptors density and lead to loss of sensation or increased pain 
(Cohen and Mao, 2014). Clinical correlates of peripheral neuropathic pain include 
hyperalgesia, burning pain, dysesthesias and paresthesias. There are few types of 
peripheral neuropathic pain syndromes, which comprise of alcoholic polyneuropathy, 
chemotherapy-induced neuropathy, complex regional pain syndrome, diabetic 
peripheral neuropathy, entrapment neuropathies, HIV sensory neuropathy, 
neuropathy secondary to tumor infiltration, phantom limb pain, postherpetic 
neuralgia, postmastectomy pain, radiculopathy, and trigeminal neuralgia. 
 
1.4 Diabetic Neuropathy  
1.4.1 Diabetic Peripheral Neuropathy (DPN)  
DPN is defined as pain arising as a direct consequence of abnormalities in the 
peripheral somatosensory system among diabetes mellitus patients (Treed et al., 2008; 
Tesfaye et al., 2010). DPN occurs in up to 50% of diabetic patients and causes 
sensory, motor and autonomic dysfunction (Boulton et al., 2005). DPN is a 
heterogeneous disorder which includes mononeuropathy, polyneuropathy, 
plexopathy and radiculopathy. Neuropathies can be classified as symmetrical form 
which is primarily sensory and autonomic; or asymmetrical form which is sensory, 
motor, or both, as well as affecting the individual cranial or peripheral nerves 
(Simmons and Feldman, 2002). The most common form of DPN is distal 
symmetrical form, which is known as diabetic sensorimotor peripheral neuropathy or 
distal symmetric diabetic peripheral neuropathy.  
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DPN begins with signs and symptoms in the feet, indicating that the most 
distal nerve fibers are affected first. It then proceeds to affect more proximal part of 
the lower limbs and then distal part of the upper limbs. It is often described as 
stocking-glove distribution neuropathy (Said, 2007). It usually presents with sensory 
disturbance in toes or feet, and a common complaint of tingling or pricking sensation. 
Vibration sense at the toes is affected most frequently (Llewelyn, 2003). However, in 
some patients with more severe loss of sensation, it may present with symptoms in 
the hands (Boulton, 2005). DPN may or may not be accompanied with clinically 
significant symptomatic autonomic neuropathy (Llewelyn, 2003; Vinik et al., 2003). 
In addition, significant motor symptoms usually occur after autonomic neuropathy 
(Vinik et al., 2013).   
 
1.4.2 Other types of diabetic neuropathy 
Autonomic neuropathy is a type of neuropathy frequently occurring in 
diabetic patients. This includes cardiovascular disturbance and postural hypotension. 
It is usually underdiagnosed and presents abnormalities such as resting tachycardia, 
exercise intolerance, resting heart rate variability, orthostasis and increased risk of 
silent myocardial ischemia and mortality (Said, 2007).  
 
Focal and multifocal neuropathy is a less common neuropathy compared to 
DPN. It occurs mainly in patients with type 2 diabetes, and is usually seen after 50 
years old. Focal neuropathies include cranial neuropathy, limb and truncal 
neuropathy and proximal diabetic neuropathy of the lower limbs (Said, 2007). 
Multifocal diabetic neuropathy is seen in a small proportion of diabetic patients. It 
involves roots and nerves of the lower limbs, trunk and upper extremities over 
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several weeks or months, sometimes with a relapsing course. The distal parts of the 
lower limbs are involved, and proximal deficits also occur in most patients (Said et 
al., 2003).  
  
1.4.3 Mechanism of diabetic neuropathy 
Long-term hyperglycemia causes downstream metabolic cascades of 
increased polyol flux, deposition of advanced glycation end-products (AGE), 
enhanced expression of AGE receptor, and increased oxidative stress. These 
mechanisms applied to endoneurial microvessels and neural tissues results in changes 
of peripheral nerves. Polyol pathway activation due to hyperglycemia showed 
endoneurial reduction of PKC (α-isoform) activity and an increase in PKC (β-
isoform) in epineurial artery, leading to neuropathy (Yamagishi et al., 2003). 
Overexpression of human aldose reductase in transgenic mice increased polyol flux 
and developed peripheral nerve dysfunction (Yagihashi et al., 1996). In both human 
and animal diabetic nerves, AGE deposition cause injurious and direct toxicity to 
nerve tissues (Sugimoto et al., 2008). Furthermore, enhanced AGE receptor in the 
endothelial cells of transgenic mice showed delay nerve conduction velocity (Wada 
and Yagihashi, 2005). Free radicals formation due to hyperglycemia showed 
oxidative-stress tissues injury through mitochondrial changes, including release of 
cytochrome C, caspase-3 activation, altered biogenesis and fission (Leinninger et al., 
2006). Oxidative stress is also generated via activation of NADPH oxidase when 
AGE binds with AGE receptors. Then, lκBα-nuclear factor-(NF)-κB activate gene 
related cell death or survival and result in the nerve conduction delay, pain, 
degeneration of neuronal cells and demyelination of Schwann cells (Yagihashi et al., 
2011). On the other hand, nerve tissues in diabetes undergo pro-inflammatory 
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process and develop neuropathy by inducing the release of cytokines and suppression 
of neurotrophins and migration of macrophages. The development of peripheral 
nerve pathology is also promoted by the presence of cellular components of bone 
marrow and ischemia (Yagihashi et al., 2011).  
  
1.4.4 Diagnostic methods for DPN  
In order to fully classify neuropathy, the assessment such as clinical 
symptoms, clinical signs, electrodiagnostic studies, quantitative sensory testing and 
autonomic function testing is needed. Nerve biopsy is not necessary (American 
Diabetes Association, 1988; Cornblath, 2004). People with diabetes should examine 
their feet annually to identify high-risk conditions. There are several different tests to 
screen and assess DPN, including reflex testing, superficial pain testing, light touch 
perception, vibration testing, sympathetic skin response, quantitative sensory testing 
and nerve conduction testing. 
 
For reflex testing, it is common to test all reflexes especially ankle reflex as it 
is most sensitive to early DPN. The examination is performed by gently striking with 
a reflex hammer, the foot dorsiflexes and Achilles tendon, when the patient is sitting 
or kneeling (Cornblath, 2004). It can be repeated with reinforcement if no reflex is 
observed. Results are scored according to the neuropathy composite score. 
 
In superficial pain testing, pain sensation is tested with a sterile safety pin and 
the patient is asked if they feel it at all, and whether the feeling is sharp or dull. The 
site of testing may include the dorsum of the great toe or the plantar aspect of the 
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distal first, third and fifth toe of each foot (Cornblath, 2004). Results are scored 
accordingly. 
 
The best calibrated device to test for light touch perception is the Semmes-
Weinstein 10-g monofilament. This instrument provides a specific force that is 10 
times the log of the force in milligrams exerted at the tip of the filament. Patients 
with diabetes or Hansen‘s disease with neuropathic ulcer could not sense the 10-g 
filament (Birke and Sims, 1986; Lee et al., 2003). Patients without neuropathy 
should be able to sense a 0.4-g monofilament. The inability to sense monofilament of 
1g and above is considered consistent with neuropathy (Tanenberg, 2009).   
 
The sensitivity to vibration in the feet is checked using a 128Hz tuning fork. 
In the early stages of DPN, patients will show a deficit in the vibration perception of 
the great toes. As the condition progresses, the deficit will expand to metatarsal-
phalangeal joints, dorsum of the foot, ankle and the mid-tibial region (Tanenberg, 
2009).   
 
Symphathetic skin measurement by quantitative sudomotor axon reflex 
testing (QSART) checks the changes in the skin potential. Increase of sweat 
production, which is a sign of axonal excitability, is seen in diabetic neuropathy 
(Illigens and Gibbons, 2009). On the other hand, quantitative sensory testing 
diagnoses the differentiation of relative deficit between small and large diameter 
axons and between peripheral neuropathy and mononeuropathy (Cornblath, 2004). 
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Nerve conduction test is used to assess the presence and severity of peripheral 
nerve injury in diabetic patients. This test can be performed with surface or needle 
electrodes. Surface techniques are widely used, easier to perform, and more 
comfortable. Nerve conduction study results show amplitudes, distal latency of 
compound muscle action and sensory potentials, conduction velocity of fastest 
conducting fibers and minimal F-wave latencies. Results of nerve conduction study 
do not always correlate well with symptoms and signs as some electro diagnostic 
abnormalities reflect metabolic changes that are not associated with symptoms (Vinik 
et al., 2003; Cornblath, 2004).  
 
1.4.5 Composite Score of Neuropathy 
Various clinical composite scores have been developed and used to quantify 
the severity of neuropathy. Each composite system has its advantage and 
disadvantage. There are few instruments that are developed to evaluate at least 3 
prominent domains affected by DPN, namely motor, sensory and autonomic. The 
Complete Neuropathy Assessment Symptom and Change score, the Neuropathy 
Impairment Score, Lower Limb Function test, Toronto Clinical Scoring System, 
Total Neuropathy Score, Total Symptom Score and the Michigan Diabetic 
Neuropathy Score are frequently used for neuropathy diagnosis in clinical trials, with 
and without the use of standard electrophysiology (Cornblath et al., 1999; Ziegler et 
al., 1999; Bril et al., 2002; Dyck et al., 2002).  
 
1.4.6 Treatment  
Four systematically active classes of drugs, namely calcium channel 
modifying anticonvulsants (e.g., pregabalin, gabapentin), sodium channel blockers 
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(e.g., carbamazepine, oxcarbazepine), tricyclic antidepressants (e.g., duloxetine, 
venlafaxine) and opiates are helpful in managing DPN symptoms (Baron, 2006).  
 
Tricyclic antidepressants (TCA), calcium channel α2-δ ligands, and 
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) are the first line regimen for 
DPN. The actions of these agents are through the inhibition of the reuptake of 
norepinephrine and serotonin (Edwards et al., 2008). Amitriptyline, desipramine, 
imipramine, clomipramine, and nortriptyline are effective TCA in relieving DPN 
symptoms. Amitriptyline and imipramine, which are serotonin inhibitors, have a 
number needed to treat (NNT) of 2.1 to obtain one patient with 50% pain reduction 
(Finnerup et al., 2005). Desipramine, which is a noradrenaline reuptake inhibitor, has 
a NNT of 2.5 to obtain one patient with 50% pain reduction (Finnerup et al., 2005). 
However, amitriptyline shows significant side effects, including dry mouth, sedation 
and blurred vision (Edwards et al., 2008). Generally, secondary amines (e.g. 
nortriptyline, desipramine) are tolerated better than tertiary amines (e.g. amitriptyline, 
imipramine) (Dworkin et al., 2007). In patients with other complications such as 
cardiac arrhythmias, heart failure, orthostatic hypotension, urinary retention or 
glaucoma, caution should be taken when using TCA (Simmons et al., 2002). 
Selective serotonin reuptake inhibitors (SSRI) such as fluoxetine, paroxetine, 
citalopram and tramadol, have largely replaced TCA due to better tolerability. 
Furthermore, duloxetine and venlafaxine which are selective noradrenaline reuptake 
inhibitors (SNRI), alleviates DPN better than SSRI. Generally, duloxetine is tolerated 
better than venlafaxine as venlafaxine consumption increases the risk of cardiac 
changes (Rowbotham et al., 2004). A trial revealed the NNT of 5.1 after taking 
duloxetine (Wernicke et al., 2006). On the other hand, gabapentin (α2-δ ligands) 
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works by binding at the site of voltage gated calcium channels, producing analgesia, 
decreasing calcium influx and reducing DPN. The NNT for gabapentin is 3.9 
(Finnerup et al., 2005). Moreover, it is well tolerated and more effective in relieving 
DPN, while common side effects include dizziness, ataxia, sedation, edema and 
weight gain (Dworkin et al., 2007).  
 
The second line of DPN treatments include tramadol and opiates. Tramadol is 
a weak agonist that inhibits serotonin reuptake. It acts on monoaminergic receptors 
indirectly and opioid mechanisms directly (Onal et al., 2007). In addition, it also acts 
centrally in blocking pain perception (St. Onge and Miller, 2008). The NNT to 
achieve 50 percent pain reduction after taking tramadol is 3.8 (Hollingshead et al., 
2006). Trial result showed that tramadol relieves DPN significantly over placebo 
(Sindrup et al., 1999). In the study conducted by Freeman and coworkers (2007), 
tramadol/acetaminophen combination was shown to be effective in relieving DPN. 
Despite its efficacy, tramadol has side effects of nausea, constipation, headache and 
dyspepsia (Edwards et al., 2008). Opiates, which include morphine and oxycodon, 
are effective in alleviating DPN. The use of opiates was evaluated in a 2006 
Cochrane review. Clinical study showed a modest pain reduction of 20% to 30% in a 
portion of patients taking opiates (Eisenberg et al., 2006; McNicol et al., 2013). In 
another design, oxycodon treatment was effective at a maximum dose of 80mg/day 
(Watson et al., 2003). However, the side effects of opiates include constipation, 
urinary retention, impaired cognitive and immune function (Edwards et al., 2008).  
 
Furthermore, third line treatments include anti-epileptics, selective serotonin 
reuptake inhibitors (SSRIs), N-methyl- D-aspartate (NMDA) receptor blockers, 
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mexiletine and topical capsaicin. Anti-epileptics drugs include carbamazepine, 
lamotrigine, valproate, topiramate and pregabalin. Carbamazepine, lamotrigine and 
valproate act as sodium channel blockers peripherally, whereas topiramate acts as  
sodium channel and Gaba receptor blocker. Pregabalin blocks pain perception by 
acting at the GABA receptor (Huizinga and Petlier, 2007). The NNT for topiramate 
is 7.4 and thus this drug is not highly efficacious to treat DPN. For gabapentin, the 
NNT is 3.9 with few side effects such as dizziness and sedation. Pregabalin causes 
less sedation than gabapentin, with a NNT of 4.2 (Finnerup et al., 2005; Huizinga 
and Petlier, 2007). On the other hand, mexilitine (anti-arrythmia medication) has 
shown a greater than 50% reduction in pain scores and it benefits those patients with 
burning pain, heat sensation and formication (Stracke et al., 1992; Edwards et al., 
2008). The NMDA receptor blocker, dextromethorphan, produces a dose-dependent 
decrease in DPN treatment. Side effects of NMDA blockers include sedation, dry 
mouth and gastrointestinal distress (Edwards et al., 2008).  Besides, topical 
medication such as capsaicin cream stimulates C fibers to release and then deplete 
substance P in order to cause the skin to be insensitive to pain. The NNT for 
capsaicin is 6.4 at 4 weeks of treatment (Mason et al., 2004). In addition, topical 
lidocaine which blocks neuronal sodium channel has been revealed to have a NNT 
for 50% pain reduction of 4.4 (Meier et al., 2003; Lindsay et al., 2010).       
 
1.5 Homocysteine 
1.5.1 Introduction 
Methionine and cysteine are sulfur containing amino acids, which play a 
crucial role in cells as a substrate for protein synthesis, as a methyl donor and for the 
synthesis of sulfur-containing compounds (intracellular tripeptide and gluthathione). 
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During the metabolism of methionine to cysteine, homocysteine being the 
intermediary metabolite is formed. Homocysteine is not present in food but is 
generated from methionine (Mudd, 1979; Singla et al., 2014). The transformation of 
homocysteine through the remethylation and transsulfuration pathway is shown in 
Figure 1.2. Homocysteine is remethylated back to methionine or converted to 
cysteine by the transsulfuration pathway. In the remethylation pathway, 
homocysteine receives a methyl group through either the methionine synthase 
dependent route or through the betaine:homocysteine methyltransferase dependent 
route. In the transsulfuration pathway, cysteine is synthesised from homocysteine, 
which represents the loss of methionine carbon skeleton (Hoffer, 2004; Brosnan and 
Brosnan, 2006).      
 
1.5.2 Factors that affect Homocysteine metabolic pathway 
In the remethylation pathway, the methionine dependent route requires the 
cooperation of water and soluble vitamins such as folate, cobalamin and riboflavin.  
Meanwhile, the betaine:homocysteine methyltransferase dependent route requires 
betaine as a methyl donor (Hoffer, 2004; Rafii et al., 2009). On the other hand, the 
transsulfuration pathway requires enzyme cystathionine-β-synthase which catalyses 
homocysteine and serine to form cysthathionine and enzyme cystathionine-γ-lyase 
which metabolises cystathionine to form cysteine (Brosnan and Brosnan, 2006; Rafii 
et al., 2009). Hyperhomocysteinemia is defined as homocysteine level of above 15 
µmol/L (Refsum et al., 1998; Ganguly and Alam, 2015). It is caused by nutrient 
status deficiency, presence of nitric oxide, genetic defects such as cystathionine-β-
synthase deficiency and methyltetrahydrofolate reductase deficiency; or certain 
diseases including renal disease and diabetes (Fowkers et al., 2000; Monsen and 
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Figure 1.2 Homocysteine formation, remethylation and transsulfuration pathways (Smolders et al., 2005). THF, Tetrahydrofolate; MS, 
Methionine Synthase; BHMT, Betaine-homocysteine Methyltransferase; CBS, cystathionine-β-synthase; B6, vitamin B6; B12, vitamin B12.  
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Ueland, 2003; Shelnutt et al., 2004; Picker and Levy, 2004; Guldener, 2006). 
 
1.5.3 Complications of High Homocysteine 
Dysregulation in the metabolism of homocysteine is implicated in adverse 
clinical outcomes, including high risk of stroke, cardiovascular diseases, Alzheimer‘s 
disease, cognitive impairment in the elderly, dementia, osteoporosis, peripheral 
neuropathy, and neural tube defects in pregnant woman. (Diaz-Arrastia, 2000; 
Ambrosch et al., 2001; Faraci, 2003; Selhub, 2008).   
 
The presence of high homocysteine exaggerates the prevalence of DPN and 
exacerbates preexisting diabetic neuropathy. Hyperhomocysteinemia has been 
reported in clinical studies as an independent risk factor associated with diabetic 
neuropathy (Ambrosch et al., 2001; Li et al., 2011; Gonzalez et al., 2012). 
Homocysteine promotes free radical formation, impairs vasodilating factors in the 
vascular wall, and injures endothelial cells (Basu et al., 2014; Baszczuk and 
Kopczynski, 2014). This in turn promotes thrombosis and arteriosclerosis 
development in the coronary arteries, cerebral arteries, arteries in kidneys and 
peripheral nerves (Brattstrom et al., 1990; Suwaidi et al., 2000; Asfar and Safar, 
2007). In addition, elevated plasma homocysteine enhances the excitotoxicity and 
oxidative-stress injury of neuronal cells, causing neuropathy (Mattson and Shea, 
2003; Luo et al., 2014). 
 
1.5.4 Analysis methods to determine Homocysteine 
Plasma or serum homocysteine exist in two forms, the oxidised form and the 
reduced form. In order to measure homocysteine, serum or plasma homocysteine is 
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treated with reductant to reduce them to total homocysteine. There are various 
methods in analysing total homocysteine, including enzyme and immunoassay, high 
performance liquid chromatography with UV, fluorescence or electrochemical 
detection, gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography tandem mass spectrometry (Fiskerstrand et al., 1993; Ducros et al., 
1999; Ubbink, 2000; Shinohara et al., 2001; Cole et al., 2004; Iciek et al., 2004;  
Windelberg et al., 2005; Kuhn et al., 2006; Weaving et al., 2006; Rafii et al., 2007).  
 
1.6 Scope of Study 
Diabetes mellitus which is a long term metabolic disorder, is common with 
additional complications such as DPN. The interest in finding the potential risk 
factors of DPN leads us to conduct this research study with the following objectives: 
A) To study the risk factors of diabetic peripheral neuropathy (DPN) by correlating 
the demographic variables and biochemistry profile with the neuropathy composite 
scores. 
B) To develop and validate a quantitative LC-MS/MS method to measure human 
plasma homocysteine. 
C) To study the association between homocysteine and the development of DPN. 
  
 
 
 
 
 
 
